yep, need to get that delayed US partner sales first imho
26 Mar '13
results out April, may wait a bit? The Board expects revenues for the full year of approximately £7.2 million (2011/12 £7.1million). LiDCO received no license fees during this financial year (2011/12: £540,000) therefore excluding license fees, revenues increased by approximately 9%. During the year overheads were tightly controlled and LiDCO product margins remained strong. The Board had anticipated signing a new US distribution agreement with a license fee ahead of the year end, but as referred to above, discussions remain ongoing with a number of parties. The absence of this revenue, coupled with the investment in the US, will result in a small operating loss for the year, although the business remains EBITDA positive
26 Mar '13
AT et al
Terry O'Brien, Chief Executive Officer of LiDCO, commented: "LiDCO's PC based monitor LiDCOrapidv2 is a multi-parameter platform that can address the potential global high risk surgery disposable market of $2 billion per annum. The US clearance for sale of LiDCO's new monitor, which combines fluid monitoring and depth of anesthesia in a single display, allows the Company to commence sales in the world's largest fluid market for these parameters. The Board estimates that 3.4 million patients are suitable for monitoring in the US alone. The next near term milestone for LiDCO in the US will be the additional registration for the display of the non-invasive blood pressure module option that, when available, is expected to substantially further expand LiDCO's market opportunity."
15 Mar '13
Looks ok here
Dr Terry O'Brien, Chief Executive Officer of LiDCO, commented: "Last year LiDCO concluded its most significant product development for a number of years (LiDCOrapid v2 with Unity software), opened up the Japanese market and achieved further significant growth in its UK domestic market for surgical products. "Sales excluding license fees advanced in the year by 9%. The NHS drive for adoption is potentially adding 40,000 new high risk surgical patients that require our monitoring. We therefore expect significant sales growth in 2013, driven by higher direct sales revenues in both the US and the UK, sales of our new and more widely applicable integrated non-invasive & depth of anesthesia product and a growing sales contribution from Japan."
15 Mar '13
Major Shareholders As at 15 February 2013, shareholders holding more than 3% of the issued share capital of LiDCO Group Plc were: Ingalls & Snyder LLC 26,844,062 13.85% Liontrust Asset Management 15,306,803 7.90% H J Leitch 14,481,183 7.47% Cheviot Asset Management Limited 13,521,480 6.98% P A Brewer 12,884,747 6.65% T K O’Brien (Director) 11,516,563 5.94% Octopus Investments Limited 10,415,730 5.38% R M Greenshields 8,899,550 4.59% D M Band 7,160,832 3.70% Hargreave Hale & Co
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.